TheStreet's Analyst Adam Feuerstein States FDA Grim on Safety of Alexza Pharmaceuticals' ADASUVE Drug

Adam Feuerstein, senior biotech analyst at TheStreet,

from the Alexza Pharmaceutical/FDA conference for its ADASUVE drug, stating that the FDA is "painting a grimmer safety picture...". Hinting that the approval might not go through. Shares of Alexza Pharmaceuticals

are currently halted.